| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 5.98 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Ligand-mediated targeted liposomes have the potential to increase the therapeutic efficacy of anticancer drugs. This work aimed to evaluate the ability of antagonist G, a peptide targeting agent capable of blocking the action of multiple neuropeptides, to selectivity improve targeting and internalization of liposomal formulations (long-circulating liposomes, LCL, and stabilized antisense lipid particles containing ionizable amino lipid, SALP) to H69 and H82 small cell lung carcinoma (SCLC) cell lines. Antagonist G-targeted LCL and SALP were prepared by two different methods (either by direct covalent linkage at activated PEG grafted onto the liposomal surface or by post-insertion of DSPE-PEG-antagonist-G-conjugates into pre-formed liposomes). Association of the liposomal formulations with target SCLC cells was studied by fluorescence microscopy using fluorescence-labeled liposomes and confirmed quantitatively with [3H]-CHE-labelled liposomes. An antisense oligodeoxynucleotide against the overexpressed oncogene c-myc(as(c-myc)) was efficiently loaded into SALP formulations, the encapsulation efficiency decreased due to the inclusion of the targeting ligand. Also, liposome size was affected by as(c-myc) physical-chemical properties. The amount of antagonist G linked to the surface of the liposomal formulations was dependent on the coupling method and lipid composition used. Covalent attachment of antagonist G increased liposomes' cellular association and internalization via receptor-mediated and clathrin-dependent endocytosis, as assessed in SCLC cell lines. Biodistribution studies in healthy mice revealed a preferential lung accumulation of antagonist G-targeted SALP as compared to the non-targeted counterpart. Lung levels of the former were up to 3-fold higher 24 h after administration, highlighting their potential to be used as delivery vectors for SCLC treatment.
Description
FCT_UID/Multi/00612/2019. FCT_UIDB/00100/2020. FCT_UIDP/00100/2020.
Keywords
Antineoplastic agents Therapeutic use Drug delivery systems Liposomes Lung neoplasms Drug therapy Oligopeptides Small cell lung carcinoma Tissue distribution FCT_UID/Multi/00612/2019 FCT_UIDB/00100/2020 FCT_UIDP/00100/2020
Citation
Carvalheiro M, Ferreira-Silva M, Holovanchuk D, Marinho S, Moreira JN, Soares H, et al. Antagonist G-targeted liposomes for improved delivery of anticancer drugs in small cell lung carcinoma. Int J Pharmaceutics. 2022;612:121380.